Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.
2.

Does it Matter Whether Canada's Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?

Hoch JS, Beca J, Sabharwal M, Livingstone SW, Fields AL.

Pharmacoeconomics. 2015 Aug;33(8):879-82. doi: 10.1007/s40273-015-0278-7. No abstract available.

3.

Thrombocytopenia in the pediatric burn patient.

Warner P, Fields AL, Braun LC, James LE, Bailey JK, Yakuboff KP, Kagan RJ.

J Burn Care Res. 2011 May-Jun;32(3):410-4. doi: 10.1097/BCR.0b013e318217f91b.

PMID:
21422941
4.

Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer.

Fields AL, Keller A, Schwartzberg L, Bernard S, Kardinal C, Cohen A, Schulz J, Eisenberg P, Forster J, Wissel P.

J Clin Oncol. 2009 Apr 20;27(12):1941-7. doi: 10.1200/JCO.2008.18.5710. Epub 2009 Mar 9.

PMID:
19273708
5.

Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials.

Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, Nitti D, Torri V, Elias D, O'Callaghan C, Langer B, Martignoni G, Bouché O, Lazorthes F, Van Cutsem E, Bedenne L, Moore MJ, Rougier P.

J Clin Oncol. 2008 Oct 20;26(30):4906-11. doi: 10.1200/JCO.2008.17.3781. Epub 2008 Sep 15.

PMID:
18794541
6.

Characterization of alterations of Rb2/p130 tumor suppressor in all-trans-retinoic acid resistant SK-OV3 ovarian carcinoma cells.

Fields AL, Soprano DR, Soprano KJ.

J Cell Physiol. 2008 Oct;217(1):77-85. doi: 10.1002/jcp.21477.

PMID:
18446820
7.

Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).

Fields AL, Einstein MH, Novetsky AP, Gebb J, Goldberg GL.

Gynecol Oncol. 2008 Jan;108(1):201-6. Epub 2007 Nov 8.

PMID:
17997145
8.

Retinoids in biological control and cancer.

Fields AL, Soprano DR, Soprano KJ.

J Cell Biochem. 2007 Nov 1;102(4):886-98. Review.

PMID:
17902161
9.

Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.

Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields AL, Mayer RJ.

J Clin Oncol. 2007 Aug 10;25(23):3456-61.

PMID:
17687149
10.

Efficacy and toxicity of concomitant cisplatin with external beam pelvic radiotherapy and two high-dose-rate brachytherapy insertions for the treatment of locally advanced cervical cancer.

Novetsky AP, Einstein MH, Goldberg GL, Hailpern SM, Landau E, Fields AL, Mutyala S, Kalnicki S, Garg M.

Gynecol Oncol. 2007 Jun;105(3):635-40. Epub 2007 Feb 27.

PMID:
17331568
11.

Survival and toxicity differences between 5-day and weekly cisplatin in patients with locally advanced cervical cancer.

Einstein MH, Novetsky AP, Garg M, Hailpern SM, Huang GS, Glueck A, Fields AL, Kalnicki S, Goldberg GL.

Cancer. 2007 Jan 1;109(1):48-53.

12.

Total pelvic exenteration: the Albert Einstein College of Medicine/Montefiore Medical Center Experience (1987 to 2003).

Goldberg GL, Sukumvanich P, Einstein MH, Smith HO, Anderson PS, Fields AL.

Gynecol Oncol. 2006 May;101(2):261-8. Epub 2006 Jan 19.

PMID:
16426668
13.

How often should a port-A-cath be flushed?

Kuo YS, Schwartz B, Santiago J, Anderson PS, Fields AL, Goldberg GL.

Cancer Invest. 2005;23(7):582-5.

PMID:
16305984
14.

Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium.

Yi-Shin Kuo D, Timmins P, Blank SV, Fields AL, Goldberg GL, Murgo A, Christos P, Wadler S, Runowicz CD.

Gynecol Oncol. 2006 Jan;100(1):160-5. Epub 2005 Sep 29.

PMID:
16198398
15.

A longitudinal study of exercise barriers in colorectal cancer survivors participating in a randomized controlled trial.

Courneya KS, Friedenreich CM, Quinney HA, Fields AL, Jones LW, Vallance JK, Fairey AS.

Ann Behav Med. 2005 Apr;29(2):147-53.

PMID:
15823788
16.

Predictors of adherence and contamination in a randomized trial of exercise in colorectal cancer survivors.

Courneya KS, Friedenreich CM, Quinney HA, Fields AL, Jones LW, Fairey AS.

Psychooncology. 2004 Dec;13(12):857-66.

PMID:
15386794
18.
19.

A randomized trial of exercise and quality of life in colorectal cancer survivors.

Courneya KS, Friedenreich CM, Quinney HA, Fields AL, Jones LW, Fairey AS.

Eur J Cancer Care (Engl). 2003 Dec;12(4):347-57.

PMID:
14982314
20.

Systematic review of management of colorectal cancer in elderly patients.

Au HJ, Mulder KE, Fields AL.

Clin Colorectal Cancer. 2003 Nov;3(3):165-71. Review.

PMID:
14706175
21.

Evaluation of low-dose intraperitoneal interferon-alpha for palliation of ascites in patients with non-ovarian gynecologic malignancies.

Khabele D, Runowicz CD, Fields AL, Anderson PS, Goldberg GL.

Gynecol Oncol. 2003 Jun;89(3):420-3.

PMID:
12798705
22.

Extended-field radiotherapy and high-dose-rate brachytherapy in carcinoma of the uterine cervix: clinical experience with and without concomitant chemotherapy.

Sood BM, Gorla GR, Garg M, Anderson PS, Fields AL, Runowicz CD, Goldberg GL, Vikram B.

Cancer. 2003 Apr 1;97(7):1781-8.

23.

Current therapies in ovarian cancer.

Fields AL, Runowicz CD.

Cancer Invest. 2003;21(1):148-56. Review. No abstract available.

PMID:
12643016
24.

Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.

Cripps MC, Figueredo AT, Oza AM, Taylor MJ, Fields AL, Holmlund JT, McIntosh LW, Geary RS, Eisenhauer EA.

Clin Cancer Res. 2002 Jul;8(7):2188-92.

25.

Two fractions of high-dose-rate brachytherapy in the management of cervix cancer: clinical experience with and without chemotherapy.

Sood BM, Gorla G, Gupta S, Garg M, Deore S, Runowicz CD, Fields AL, Goldberg GL, Anderson PS, Vikram B.

Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):702-6.

PMID:
12062615
26.

Allelotype of papillary serous peritoneal carcinomas.

Cass I, Baldwin RL, Fasylova E, Fields AL, Klinger HP, Runowicz CD, Karlan BY.

Gynecol Oncol. 2001 Jul;82(1):69-76.

PMID:
11426964
27.

Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas.

Cass I, Li AJ, Runowicz CD, Fields AL, Goldberg GL, Leuchter RS, Lagasse LD, Karlan BY.

Gynecol Oncol. 2001 Jan;80(1):56-61.

PMID:
11136570
28.

Clinical survival predictors in patients with advanced cancer.

Viganó A, Bruera E, Jhangri GS, Newman SC, Fields AL, Suarez-Almazor ME.

Arch Intern Med. 2000 Mar 27;160(6):861-8.

PMID:
10737287
29.

Ovarian carcinoid: management of primary and recurrent tumors.

Timmins PF, Kuo DY, Anderson PS, Fields AL, Whitney KD, Goldberg GL.

Gynecol Oncol. 2000 Jan;76(1):112-4.

PMID:
10620451
30.

Screening for gynecologic malignancies: A continuing responsibility.

Runowicz CD, Fields AL.

Surg Oncol Clin N Am. 1999 Oct;8(4):703-23, vii. Review.

PMID:
10452936
31.

Colony-stimulating factor-1 and its receptor do not have a role in the pathogenesis of uterine sarcomas.

Anderson PS, Smith HO, Goldberg GL, Fields AL, Runowicz CD, Pollard JW.

Gynecol Oncol. 1999 Aug;74(2):202-7.

PMID:
10419732
32.

Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma.

Warner E, Jensen JL, Cripps C, Khoo KE, Goel R, Kerr IA, Bjarnason GA, Fields AL, Hrincu A.

Acta Oncol. 1999;38(2):255-9.

PMID:
10227449
33.

Compliance with Papanicolaou smear screening following tubal ligation in women with cervical cancer.

Winkler HA, Anderson PS, Fields AL, Runowicz CD, DeVictoria C, Goldberg GL.

J Womens Health. 1999 Jan-Feb;8(1):103-7.

PMID:
10094087
34.

Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan.

Cass I, Kuo DY, Fields AL, Runowicz CD, Goldberg GL.

Gynecol Oncol. 1998 May;69(2):175-8. No abstract available.

PMID:
9600828
35.

Pelvic exenteration for cervix cancer: would additional intraoperative interstitial brachytherapy improve survival?

Beitler JJ, Anderson PS, Wadler S, Runowicz CD, Hayes MK, Fields AL, Sood B, Goldberg GL.

Int J Radiat Oncol Biol Phys. 1997 Apr 1;38(1):143-8.

PMID:
9212016
36.

Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer.

Comerci JT Jr, Fields AL, Runowicz CD, Goldberg GL.

Gynecol Oncol. 1997 Mar;64(3):425-30.

PMID:
9062144
37.

Induction of transforming growth factor beta-1 in cervical intraepithelial neoplasia in vivo after treatment with beta-carotene.

Comerci JT Jr, Runowicz CD, Fields AL, Romney SL, Palan PR, Kadish AS, Goldberg GL.

Clin Cancer Res. 1997 Feb;3(2):157-60.

38.

Endometrioid adenocarcinoma of the ovary and long-term tamoxifen therapy: a coincidence or a cause for concern?

Kuo DY, Jones J, Fields AL, Runowicz CD, Goldberg GL.

Eur J Gynaecol Oncol. 1997;18(6):457-60.

PMID:
9443009
39.

Analysis of MDR1 expression in normal and malignant endometrium by reverse transcription-polymerase chain reaction and immunohistochemistry.

Kuo DY, Mallick S, Shen HJ, DeVictoria C, Jones J, Fields AL, Goldberg GL, Runowicz CD, Horwitz SB.

Clin Cancer Res. 1996 Dec;2(12):1981-92.

40.

The genetics of ovarian cancer: an assessment of current screening protocols and recommendations for counseling families at risk.

Bombard AT, Fields AL, Aufox S, Ben-Yishay M.

Clin Obstet Gynecol. 1996 Dec;39(4):860-72. Review.

PMID:
8934036
41.

Mature results of a phase II trial of concomitant cisplatin/pelvic radiotherapy for locally advanced squamous cell carcinoma of the cervix.

Fields AL, Anderson PS, Goldberg GL, Wadler S, Beitler J, Sood B, Runowicz CD.

Gynecol Oncol. 1996 Jun;61(3):416-22.

PMID:
8641625
42.

Altered expression of transforming growth factor-beta 1 in cervical neoplasia as an early biomarker in carcinogenesis of the uterine cervix.

Comerci JT Jr, Runowicz CD, Flanders KC, De Victoria C, Fields AL, Kadish AS, Goldberg GL.

Cancer. 1996 Mar 15;77(6):1107-14.

PMID:
8635131
43.

Squamous cell carcinoma in mature cystic teratoma in a young woman: a diagnostic and management dilemma.

Comerci JT Jr, Jones JG, Fields AL, Runowicz CD, Goldberg GL.

Eur J Gynaecol Oncol. 1996;17(6):501-3. Review.

PMID:
8971527
44.

Promising new therapies in the treatment of advanced ovarian cancer.

Runowicz CD, Fields AL, Goldberg GL.

Cancer. 1995 Nov 15;76(10 Suppl):2028-33. Review.

PMID:
8634995
45.

Long-term follow-up of stage I cervical adenocarcinoma treated by radical surgery.

McLellan R, Dillon MB, Woodruff JD, Heatley GJ, Fields AL, Rosenshein NB.

Gynecol Oncol. 1994 Feb;52(2):253-9.

PMID:
8314148
46.

Effects of systemic inhibition of prostaglandin production on protein metabolism in tumor-bearing rats.

Strelkov AB, Fields AL, Baracos VE.

Am J Physiol. 1989 Aug;257(2 Pt 1):C261-9.

PMID:
2764090
48.

Accelerated loss of lean body mass in fasting rats due to activation of pyruvate dehydrogenase by dichloroacetate.

Fields AL, Falk N, Cheema-Dhadli S, Halperin ML.

Metabolism. 1987 Jul;36(7):621-4.

PMID:
3600275
49.

Erosive gastroduodenitis with marked epithelial atypia after hepatic arterial infusion chemotherapy.

Jewell LD, Fields AL, Murray CJ, Thomson AB.

Am J Gastroenterol. 1985 Jun;80(6):421-4.

PMID:
3923827
50.

Lactic acidosis--emphasis on the carbon precursors and buffering of the acid load.

Halperin ML, Fields AL.

Am J Med Sci. 1985 Apr;289(4):154-9.

PMID:
3985048

Supplemental Content

Loading ...
Support Center